|
|
 Previous Article | Table of Contents | Next Article 
Timed-sequential induction therapy improves postremission outcome in acute
myeloid leukemia: a report from the Children's Cancer Group
WG Woods, N Kobrinsky, JD Buckley, JW Lee, J Sanders, S Neudorf, S Gold, DR Barnard, J DeSwarte, K Dusenbery, D Kalousek, DC Arthur and BJ Lange
University of Minnesota, Minneapolis, MN, USA.
Timed sequencing of cycles of induction chemotherapy in acute myeloid
leukemia (AML) has been proposed as a way to achieve maximal leukemic cell
kill through recruitment and synchronization of residual neoplastic cells.
Furthermore, whether intensive induction therapy should be continued in the
presence of profound myelosuppression is an important question. The
Children's Cancer Group (CCG) conducted a prospective randomized trial in
which 589 patients with AML were randomized at diagnosis to one of two
induction approaches involving a 4-day cycle of five active
chemotherapeutic agents, with the second cycle administered either 10 days
after the first cycle, despite low or dropping blood counts (intensive
timing), or 14 days or later from the beginning of the first cycle,
depending on bone marrow status (standard timing). All patients achieving
remission received a total of four cycles of induction therapy. They were
then allocated to allogeneic bone marrow transplantation (BMT) if a
compatible family donor was present or randomized to aggressive
nonmyeloablative therapy or to myeloablative therapy with purged autologous
BMT rescue. The three postremission arms remain coded. Induction success
and median days to complete induction were similar for the 295 patients
randomized to the intensive timing arm (75%, 99 days) compared with the 294
patients randomized to the standard timing arm (70%, 105 days; P = .18 for
remission). However, a marked improvement in outcome was demonstrated in
patients randomized to the intensive timing arm, with an actuarial
event-free survival at 3 years of 42% +/- 7% (95% confidence interval [CI])
versus 27% +/- 6% for patients on the standard timing arm (P = .0005).
Disease-free survival results at 3 years from the end of induction were
superior for patients receiving intensively timed induction therapy (N =
211), 55% +/- 9% versus 37% +/- 9% for standard timing patients (N = 195, P
= .0002), with a median follow-up from achieving remission of 28 months.
Superior results were documented for patients receiving intensive timing
irrespective of the postremission therapy to which they were allocated.
Intensively timed induction therapy for patients with AML markedly improves
event-free survival, even for patients undergoing myeloablative therapy
with BMT rescue. Without controlling for the type of induction therapy
received, results of various BMT studies in AML comparing different
preparative regimens will be difficult to interpret.
Volume 87,
Issue 12,
pp. 4979-4989,
06/15/1996
Copyright © 1996 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
I. Tsukimoto, A. Tawa, K. Horibe, K. Tabuchi, H. Kigasawa, M. Tsuchida, H. Yabe, H. Nakayama, K. Kudo, R. Kobayashi, et al.
Risk-Stratified Therapy and the Intensive Use of Cytarabine Improves the Outcome in Childhood Acute Myeloid Leukemia: The AML99 Trial From the Japanese Childhood AML Cooperative Study Group
J. Clin. Oncol.,
August 20, 2009;
27(24):
4007 - 4013.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Braess, K. Spiekermann, P. Staib, A. Gruneisen, B. Wormann, W.-D. Ludwig, H. Serve, A. Reichle, R. Peceny, D. Oruzio, et al.
Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG
Blood,
April 23, 2009;
113(17):
3903 - 3910.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. P. Vaughan and J. E. Karp
The Long Road to a Cure for Acute Myelocytic Leukemia: From Intensity to Specificity
J. Clin. Oncol.,
July 20, 2008;
26(21):
3475 - 3477.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Lange, F. O. Smith, J. Feusner, D. R. Barnard, P. Dinndorf, S. Feig, N. A. Heerema, C. Arndt, R. J. Arceci, N. Seibel, et al.
Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology Group
Blood,
February 1, 2008;
111(3):
1044 - 1053.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Karp, R. M. Ricklis, K. Balakrishnan, J. Briel, J. Greer, S. D. Gore, B. D. Smith, M. A. McDevitt, H. Carraway, M. J. Levis, et al.
A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias
Blood,
September 15, 2007;
110(6):
1762 - 1769.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Hasle, T. A. Alonzo, A. Auvrignon, C. Behar, M. Chang, U. Creutzig, A. Fischer, E. Forestier, A. Fynn, O. A. Haas, et al.
Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study
Blood,
June 1, 2007;
109(11):
4641 - 4647.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Barbaric, T. A. Alonzo, R. B. Gerbing, S. Meshinchi, N. A. Heerema, D. R. Barnard, B. J. Lange, W. G. Woods, R. J. Arceci, and F. O. Smith
Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961
Blood,
March 15, 2007;
109(6):
2314 - 2321.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Jeha and F. J. Giles
Acute myeloid leukemia
ASH Self-Assessment Program,
January 1, 2007;
2007(1):
243 - 252.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Aplenc, T. A. Alonzo, R. B. Gerbing, F. O. Smith, S. Meshinchi, J. A. Ross, J. Perentesis, W. G. Woods, B. J. Lange, and S. M. Davies
Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group
Blood,
July 1, 2006;
108(1):
74 - 80.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Johnston, T. A. Alonzo, R. B. Gerbing, B. J. Lange, and W. G. Woods
Risk Factors and Therapy for Isolated Central Nervous System Relapse of Pediatric Acute Myeloid Leukemia
J. Clin. Oncol.,
December 20, 2005;
23(36):
9172 - 9178.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Ortega, L. Madero, G. Martin, A. Verdeguer, P. Garcia, R. Parody, J. Fuster, A. Molines, A. Novo, G. Deben, et al.
Treatment With All-Trans Retinoic Acid and Anthracycline Monochemotherapy for Children With Acute Promyelocytic Leukemia: A Multicenter Study by the PETHEMA Group
J. Clin. Oncol.,
October 20, 2005;
23(30):
7632 - 7640.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Ross, R. Mahfouz, M. Onciu, H.-C. Liu, X. Zhou, G. Song, S. A. Shurtleff, S. Pounds, C. Cheng, J. Ma, et al.
Gene expression profiling of pediatric acute myelogenous leukemia
Blood,
December 1, 2004;
104(12):
3679 - 3687.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Tse, S. Meshinchi, T. A. Alonzo, D. L. Stirewalt, R. B. Gerbing, W. G. Woods, F. R. Appelbaum, and J. P. Radich
Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia
Blood,
November 15, 2004;
104(10):
3058 - 3063.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Castaigne, S. Chevret, E. Archimbaud, P. Fenaux, D. Bordessoule, H. Tilly, T. de Revel, M. Simon, B. Dupriez, M. Renoux, et al.
Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study
Blood,
October 15, 2004;
104(8):
2467 - 2474.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Godder, M. Eapen, J. H. Laver, M.-J. Zhang, B. M. Camitta, A. S. Wayne, R. P. Gale, J. J. Doyle, L. C. Yu, A. R. Chen, et al.
Autologous Hematopoietic Stem-Cell Transplantation for Children With Acute Myeloid Leukemia in First or Second Complete Remission: A Prognostic Factor Analysis
J. Clin. Oncol.,
September 15, 2004;
22(18):
3798 - 3804.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Karp, I. Gojo, R. Pili, C. D. Gocke, J. Greer, C. Guo, D. Qian, L. Morris, M. Tidwell, H. Chen, et al.
Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias: Therapy with Sequential 1-{beta}-D-Arabinofuranosylcytosine, Mitoxantrone, and Bevacizumab
Clin. Cancer Res.,
June 1, 2004;
10(11):
3577 - 3585.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Neudorf, J. Sanders, N. Kobrinsky, T. A. Alonzo, A. B. Buxton, S. Gold, D. R. Barnard, J. D. Wallace, D. Kalousek, B. J. Lange, et al.
Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival
Blood,
May 15, 2004;
103(10):
3655 - 3661.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Lange, P. Dinndorf, F. O. Smith, C. Arndt, D. Barnard, S. Feig, J. Feusner, N. Seibel, M. Weiman, R. Aplenc, et al.
Pilot Study of Idarubicin-Based Intensive-Timing Induction Therapy for Children With Previously Untreated Acute Myeloid Leukemia: Children's Cancer Group Study 2941
J. Clin. Oncol.,
January 1, 2004;
22(1):
150 - 156.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-H. Pui, M. Schrappe, R. C. Ribeiro, and C. M. Niemeyer
Childhood and Adolescent Lymphoid and Myeloid Leukemia
Hematology,
January 1, 2004;
2004(1):
118 - 145.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. Gamis, W. G. Woods, T. A. Alonzo, A. Buxton, B. Lange, D. R. Barnard, S. Gold, and F. O. Smith
Increased Age at Diagnosis Has a Significantly Negative Effect on Outcome in Children With Down Syndrome and Acute Myeloid Leukemia: A Report From the Children's Cancer Group Study 2891
J. Clin. Oncol.,
September 15, 2003;
21(18):
3415 - 3422.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Meshinchi, D. L. Stirewalt, T. A. Alonzo, Q. Zhang, D. A. Sweetser, W. G. Woods, I. D. Bernstein, R. J. Arceci, and J. P. Radich
Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia
Blood,
August 15, 2003;
102(4):
1474 - 1479.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Wells, M. T. Adams, T. A. Alonzo, R. J. Arceci, J. Buckley, A. B. Buxton, K. Dusenbery, A. Gamis, M. Masterson, T. Vik, et al.
Mitoxantrone and Cytarabine Induction, High-Dose Cytarabine, and Etoposide Intensification for Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia: Children's Cancer Group Study 2951
J. Clin. Oncol.,
August 1, 2003;
21(15):
2940 - 2947.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Karp, D. D. Ross, W. Yang, M. L. Tidwell, Y. Wei, J. Greer, D. L. Mann, T. Nakanishi, J. J. Wright, and A. D. Colevas
Timed Sequential Therapy of Acute Leukemia with Flavopiridol: In Vitro Model for a Phase I Clinical Trial
Clin. Cancer Res.,
January 1, 2003;
9(1):
307 - 315.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Frohling, R. F. Schlenk, J. Breitruck, A. Benner, S. Kreitmeier, K. Tobis, H. Dohner, and K. Dohner
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm
Blood,
December 15, 2002;
100(13):
4372 - 4380.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. R. Crews, V. Gandhi, D. K. Srivastava, B. I. Razzouk, X. Tong, F. G. Behm, W. Plunkett, S. C. Raimondi, C.-H. Pui, J. E. Rubnitz, et al.
Interim Comparison of a Continuous Infusion Versus a Short Daily Infusion of Cytarabine Given in Combination With Cladribine for Pediatric Acute Myeloid Leukemia
J. Clin. Oncol.,
October 15, 2002;
20(20):
4217 - 4224.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. O'Brien, S. J. Russell, M. R. Vowels, C. M. Oswald, K. Tiedemann, P. J. Shaw, L. Lockwood, L. Teague, M. Rice, and G. M. Marshall
Results of consecutive trials for children newly diagnosed with acute myeloid leukemia from the Australian and New Zealand Children's Cancer Study Group
Blood,
September 26, 2002;
100(8):
2708 - 2716.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. R. Barnard, B. Lange, T. A. Alonzo, J. Buckley, J. N. Kobrinsky, S. Gold, S. Neudorf, J. Sanders, L. Burden, and W. G. Woods
Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation
Blood,
June 28, 2002;
100(2):
427 - 434.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Perel, A. Auvrignon, T. Leblanc, J.-P. Vannier, G. Michel, B. Nelken, V. Gandemer, C. Schmitt, J.-P. Lamagnere, L. De Lumley, et al.
Impact of Addition of Maintenance Therapy to Intensive Induction and Consolidation Chemotherapy for Childhood Acute Myeloblastic Leukemia: Results of a Prospective Randomized Trial, LAME 89/91
J. Clin. Oncol.,
June 15, 2002;
20(12):
2774 - 2782.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. M. Bickert
Treatment of Common Childhood Malignancies
Journal of Pharmacy Practice,
February 1, 2002;
15(1):
42 - 51.
[Abstract]
[PDF]
|
|
|
|
|
|
|
W. G. Woods, D. R. Barnard, T. A. Alonzo, J. D. Buckley, N. Kobrinsky, D. C. Arthur, J. Sanders, S. Neudorf, S. Gold, and B. J. Lange
Prospective Study of 90 Children Requiring Treatment for Juvenile Myelomonocytic Leukemia or Myelodysplastic Syndrome: A Report From the Children's Cancer Group
J. Clin. Oncol.,
January 15, 2002;
20(2):
434 - 440.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. J. Giles, A. Keating, A. H. Goldstone, I. Avivi, C. L. Willman, and H. M. Kantarjian
Acute Myeloid Leukemia
Hematology,
January 1, 2002;
2002(1):
73 - 110.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
H. Kawasaki, K. Isoyama, M. Eguchi, S. Hibi, N. Kinukawa, Y. Kosaka, T. Oda, M. Oda, S.-i. Nishimura, M. Imaizumi, et al.
Superior outcome of infant acute myeloid leukemia with intensive chemotherapy: results of the Japan Infant Leukemia Study Group
Blood,
December 15, 2001;
98(13):
3589 - 3594.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. K. H. Webb, G. Harrison, R. F. Stevens, B. G. Gibson, I. M. Hann, and K. Wheatley
Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia
Blood,
September 15, 2001;
98(6):
1714 - 1720.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Sweetser, C.-S. Chen, A. A. Blomberg, D. A. Flowers, P. C. Galipeau, M. T. Barrett, N. A. Heerema, J. Buckley, W. G. Woods, I. D. Bernstein, et al.
Loss of heterozygosity in childhood de novo acute myelogenous leukemia
Blood,
August 15, 2001;
98(4):
1188 - 1194.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. H. Athale, B. I. Razzouk, S. C. Raimondi, X. Tong, F. G. Behm, D. R. Head, D. K. Srivastava, J. E. Rubnitz, L. Bowman, C.-H. Pui, et al.
Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience
Blood,
June 15, 2001;
97(12):
3727 - 3732.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Krance, C. A. Hurwitz, D. R. Head, S. C. Raimondi, F. G. Behm, K. R. Crews, D. K. Srivastava, H. Mahmoud, W. M. Roberts, X. Tong, et al.
Experience With 2-Chlorodeoxyadenosine in Previously Untreated Children With Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Diseases
J. Clin. Oncol.,
June 1, 2001;
19(11):
2804 - 2811.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Pinkel, W. G. Woods, B. J. Lange, F. O. Smith, and T. A. Alonzo
Treatment of children with acute myeloid leukemia
Blood,
June 1, 2001;
97(11):
3673 - 3675.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Davies, L. L. Robison, J. D. Buckley, T. Tjoa, W. G. Woods, G. A. Radloff, J. A. Ross, and J. P. Perentesis
Glutathione S-Transferase Polymorphisms and Outcome of Chemotherapy in Childhood Acute Myeloid Leukemia
J. Clin. Oncol.,
March 1, 2001;
19(5):
1279 - 1287.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. B. Pawlowska, S. Hashino, H. McKenna, B. J. Weigel, P. A. Taylor, and B. R. Blazar
In vitro tumor-pulsed or in vivo Flt3 ligand-generated dendritic cells provide protection against acute myelogenous leukemia in nontransplanted or syngeneic bone marrow-transplanted mice
Blood,
March 1, 2001;
97(5):
1474 - 1482.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. G. Woods, S. Neudorf, S. Gold, J. Sanders, J. D. Buckley, D. R. Barnard, K. Dusenbery, J. DeSwarte, D. C. Arthur, B. J. Lange, et al.
A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from the Children's Cancer Group
Blood,
January 1, 2001;
97(1):
56 - 62.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Meshinchi, W. G. Woods, D. L. Stirewalt, D. A. Sweetser, J. D. Buckley, T. K. Tjoa, I. D. Bernstein, and J. P. Radich
Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia
Blood,
January 1, 2001;
97(1):
89 - 94.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Zwaan, G.-J. L. Kaspers, R. Pieters, N. L. R.-V. Woerden, M. L. den Boer, R. Wunsche, M. M. A. Rottier, K. Hahlen, E. R. van Wering, G. E. Janka-Schaub, et al.
Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia
Blood,
October 15, 2000;
96(8):
2879 - 2886.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M Chessells
Recent advances in management of acute leukaemia
Arch. Dis. Child.,
June 1, 2000;
82(6):
438 - 442.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. S. Gamis, W. B. Howells, J. DeSwarte-Wallace, J. H. Feusner, J. D. Buckley, and W. G. Woods
Alpha Hemolytic Streptococcal Infection During Intensive Treatment for Acute Myeloid Leukemia: A Report From the Children's Cancer Group Study CCG-2891
J. Clin. Oncol.,
May 9, 2000;
18(9):
1845 - 1855.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. V. Dahl, N. J. Lacayo, N. Brophy, K. Dunussi-Joannopoulos, H. J. Weinstein, M. Chang, B. I. Sikic, and R. J. Arceci
Mitoxantrone, Etoposide, and Cyclosporine Therapy in Pediatric Patients With Recurrent or Refractory Acute Myeloid Leukemia
J. Clin. Oncol.,
May 9, 2000;
18(9):
1867 - 1875.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Taub, X. Huang, L. H. Matherly, M. L. Stout, S. A. Buck, G. V. Massey, D. L. Becton, M. N. Chang, H. J. Weinstein, and Y. Ravindranath
Expression of Chromosome 21-Localized Genes in Acute Myeloid Leukemia: Differences Between Down Syndrome and Non-Down Syndrome Blast Cells and Relationship to In Vitro Sensitivity to Cytosine Arabinoside and Daunorubicin
Blood,
August 15, 1999;
94(4):
1393 - 1400.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Felix and B. J. Lange
Leukemia in Infants
Oncologist,
June 1, 1999;
4(3):
225 - 240.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
Y. Kanda, A. Miwa, A. Togawa, J. Perez-Calvo, A. Brugarolas, R. Suzuki, M. Seto, Y. Morishima, N.-C. Gorin, M. Labopin, et al.
Treatment of Acute Myeloid Leukemia
N. Engl. J. Med.,
May 6, 1999;
340(18):
1436 - 1439.
[Full Text]
|
|
|
|
|
|
|
A. E. Woolfrey, T. A. Gooley, E. L. Sievers, L. A. Milner, R. G. Andrews, M. Walters, P. Hoffmeister, J. A. Hansen, C. Anasetti, E. Bryant, et al.
Bone Marrow Transplantation for Children Less Than 2 Years of Age With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Blood,
November 15, 1998;
92(10):
3546 - 3556.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Lange, N. Kobrinsky, D. R. Barnard, D. C. Arthur, J. D. Buckley, W. B. Howells, S. Gold, J. Sanders, S. Neudorf, F. O. Smith, et al.
Distinctive Demography, Biology, and Outcome of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Children With Down Syndrome: Children's Cancer Group Studies 2861 and 2891
Blood,
January 15, 1998;
91(2):
608 - 615.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-L. Harousseau, J.-Y. Cahn, B. Pignon, F. Witz, N. Milpied, M. Delain, B. Lioure, T. Lamy, B. Desablens, F. Guilhot, et al.
Comparison of Autologous Bone Marrow Transplantation and Intensive Chemotherapy as Postremission Therapy in Adult Acute Myeloid Leukemia
Blood,
October 15, 1997;
90(8):
2978 - 2986.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
